Clear evidence of Revita activity: The study met its 3-month efficacy endpoint with strong statistical significance (p=0.014), delivering 2.5% further weight loss with Revita (n=29) even after stopping tirzepatide, versus 10% weight regain in sham-treated patients (n=16)
Perspectivas del mercado y potencial de crecimiento Se prev un crecimiento de la demanda de acetil L-carnitina y cido alfa lipoico, impulsada por el creciente inters en medidas preventivas de salud y el envejecimiento de la poblacin
Transient mood shifts or increased emotional sensitivity, particularly in patients with underlying stress-related conditions
Asia-Pacific ranks as the fastest-growing region, holding approximately 18% of the semaglutide market, with China, India, and Japan accounting for over 70% of regional consumption
FLOW is a randomised, double-blind, parallel-group, multinational, phase 3b trial comparing semaglutide with matched placebo
Minoxidil, available over the counter, is licensed for androgenetic alopecia